Optometry Times Staff Reports

US commercialization of EVO will begin immediately in select cities across the country.

The latest launches of BRIO-I and BRIO-II follow promising topline data from the phase 2 VIVD clinical study evaluating Brimochol PF.

With its portable capabilities, the Heru platform replaces legacy diagnostic devices and surpasses standard care in cost and size.

Originally postponed due to COVID-19, the annual event will now be held this June at the JW Marriott Grande Lakes in Orlando, Florida.

CSF-1 is a preservative-free solution designed as an alternative to reading glasses for patients.

The company expects to enroll patients diagnosed with keratoconus in two trials at clinical sites in the US, South America, Europe, and Asia.

SOLOS is automatic lens analyzer that enables advanced, accurate, and efficient lens analysis with one button touch.

The unique partnership and corresponding sponsorship is the largest in ASCO’s history.

The purchase gives Théa ownership over seven products across the therapeutic space, including glaucoma and ocular surface disease.

Effective this month, the coverage applies to approximately 70% of all United Healthcare commercial lives.

Daily disposable contact lenses combine with an established antihistamine for the world's first drug-eluting contact lenses.

Topline proof-of-concept data are expected by the first quarter of 2023.

In the past 12 months, the program has prevented the equivalent of 28 million plastics bottles from polluting the oceans.

Shamir joined the Alpine in May 2021 in partnership with Alpine F1 Team to enhance the visual quality and safety of its race team members.

The actress and singer-songwriter will serves as the brand ambassador for OptiLight, a new dry eye disease treatment.

The removal of preservatives may be beneficial for the ocular health of glaucoma patients

The optical technology company announced two updates to their product line.

Black EyeCare Perspective is connecting communities with Black eye care professionals, optometrists and ophthalmologists

Faricimab is now the first and only FDA-approved drug to target two distinct pathways known to cause retinal disease that may lead to vision loss.

Ahead of World Neglected Tropical Diseases (NTD) Day on Jan. 30, Alemayehu Sisay, MD, MPH, country director for Orbis Ethiopia, discusses efforts and progress the organization has made in treating patients with NTDs and how to get involved in recognizing World NTD Day.

Weigh in on our poll!

Research also highlights the top factors that lead to care, which can be used to improve parents' uptake of sight-saving surgery for their children.

The annual national conference in February will offer 3 intensive days of business management curricula, COPE-approved clinical education, staff training and high-profile guest speakers.

Positive one-year results of Genentech’s phase III trials analyzing faricimab for treatment of wet AMD and DME were released today.

Alcon has launched the latest addition to its European dry eye products portfolio: Systane Complete Preservative-Free Lubricant Eye Drop, available in an easy-to-use, multi-dose bottle, the company announced last week.

Transitions Optical's Diversity Advisory Board members share how eyecare professionals can incorporate diversity, equity and inclusion in their lives and careers.

AACO will once again be participating in a co-located meeting at SECO 2022 in New Orleans, March 9-13. AACO will be presenting 4 hours of FREE CE as well as a CE Dinner open to all Optometrists, free for AACO members.

ASCENT, RegenXBio’s Phase III clinical trial conducted in partnership with AbbVie, is expected to enroll patients in the United States and Canada, with pivotal trials expected to support BLA submission for RGX-314 in 2024.